Penntuff (codeine polistirex/chlorpheniramine polistirexl antitussive cleared FDA after 32-month review. The b.i.d. controlled release liquid employs firm's Pennkinetic technology. Announcing the approval, Pennwalt Pharmaceutical Div. President Bernard Shea said: "For the first time, patients will receive all the benefits of codeine cough control in a once-every-12-hours formulation." Product scheduled for fall launch at prices competitive to other 12 hour cough/cold formulations.
You may also be interested in...
With Reckitt's OTC sales falling 3% in 2020, the firm has committed to doubling its R&D spend in search of breakthrough product innovations.
Taiwan’s JHL Biotech has rebranded itself as Eden Biologics at the same time as it has announced progress on clinical trials for its denosumab biosimilar candidate.
Starpharma's COVID-busting Viraleze antiviral nasal spray will soon be available across Europe, included the UK. But will it fall foul of local evidence requirements, for example in France, where the country's medicines agency has halted the sale of Pharma & Beauty (P&B) Group's COV-Defense spray until its efficacy against COVID has been confirmed by human-based studies?